The Dilemma of Difference Between Randomized Control Trials and Real-Life Practice in the Treatment of Retinal Diseases with Intravitreal anti-VEGF Agents

References (5)

1. Ba J, Peng RS, Xu D, Li YH, Shi H, Wang Q, et al. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des Devel Ther 2015;9:5397–405
2. Strain WD, Cos X, Prünte C. Considerations for management of patients with diabetic macular edema: Optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration. Diabetes Res Clin Pract 2017;126:1–9
3. Lattanzio R, Torres Gimeno A, Battaglia Parodi M, Bandello F. Retinal vein occlusion: current treatment. Ophthalmologica 2011;225:135–43
4. Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: A literature review and consensus recommendations. Retina 2015;35:1489–506
5. Ozkaya A, Alkin Z, Yesilkaya C, Erdogan G, Perente I, Taskapili M. Ranibizumab in macular edema secondary to retinal vein occlusion in a real life practice: A retrospective case series. Beyoglu Eye J 2016;1:5–9.